Ayala Pharmaceuticals, Inc. (AYLA) operates as a clinical-stage oncology firm, concentrating its efforts on discovering, developing, and ultimately commercializing small molecule treatments designed for individuals afflicted by rare and aggressive cancers. A key asset in its pipeline is AL101, an injectable, potent, and highly selective small molecule gamma secretase inhibitor (GSI). This candidate is currently in Phase II clinical trials, specifically targeting recurrent or metastatic adenoid cystic carcinoma in patients whose disease is characterized by Notch-activating mutations. Additionally, the company is advancing AL102, an oral, potent, and selective small molecule GSI, which is undergoing a pivotal Phase II/III study for the management of desmoid tumors. Ayala Pharmaceuticals has also entered into a collaboration agreement with Novartis International Pharmaceutical Limited to explore the development of AL102 for addressing multiple myeloma. The company, founded in 2017, maintains its headquarters in Rehovot, Israel.